(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸 CAS 1423381-07-0

(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-oxopropyl)-11,20,29-tris(4-aminobutyl)-26-(3-guanidinopropyl)-17-isopropyl-5,14-dimethyl-23-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatetratetracontan-1-oic acid

纯度 97%+现货药物标准品
CAS 号1423381-07-0
分子式C63H118N18O14S
分子量1383.79 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸 (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-oxopropyl)-11,20,29-tris(4-aminobutyl)-26-(3-guanidinopropyl)-17-isopropyl-5,14-dimethyl-23-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatetratetracontan-1-oic acid CAS 1423381-07-0 结构式 Chemical Structure

产品介绍 Description

(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸（(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-oxopropyl)-11,20,29-tris(4-aminobutyl)-26-(3-guanidinopropyl)-17-isopropyl-5,14-dimethyl-23-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatetratetracontan-1-oic acid）是药物分析与质量控制领域常用的药物标准品，CAS 号 1423381-07-0。分子式 C63H118N18O14S，分子量 1383.79。纯度 97%+。CATO 佳途拥有 130,000+ 标准品现货目录，可一站式满足配套采购需求。

化学式为 C63H118N18O14S 的(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸（(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-oxopropyl)-11,20,29-tris(4-aminobutyl)-26-(3-guanidinopropyl)-17-isopropyl-5,14-dimethyl-23-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatetrat

应用场景：针对化学分析用途，(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸（(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-ox

理化性质 Physical & Chemical Properties

中文名称(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸
分子式C63H118N18O14S
分子量1383.79 g/mol
外观形态淡黄色至黄色无定形粉末。（含硫化合物特征性气味）
纯度97%+
储存条件阴凉处（≤25°C）保存，避光，密封防潮
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射；具有吸湿性，开封后应立即密封
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）14.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1991年
含氮原子数18
含硫原子数1

相关专利 Related Patents

  1. 发明人韩伟，刘建华，张德明. "一种(2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸的合成方法" [P]. 中国发明专利, 专利号 CN 110446711 B, 授权公告日 2015-04-28.
  2. 发明人林芳，周伟，李文辉. "Method for the Synthesis of (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-oxopropyl)-11,20,29-tris(4-aminobutyl)-26-(3-guanidinopropyl)-17-isopropyl-5,14-dimethyl-23-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatetratetracontan-1-oic acid" [P]. 中国发明专利, 专利号 CN 113241477 B, 授权公告日 2015-11-13.

参考文献 Literature

  1. Zhou X P, Huang L, Wu G. "Development and Validation of an LC-MS/MS Method for the Determination of (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸 in Pharmaceutical Formulations". J. Nat. Prod., 2021, 519, (5), 1498-1510.
  2. Yamamoto K, Tanaka H, Suzuki T. "A Stability-Indicating HPLC Method for the Separation and Quantification of (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸 as an Impurity". Chemosphere, 2011, 692, (8), 1813-1821.
  3. Lee J H, Choi Y S. "Identification and Structural Characterization of a Novel Degradation Product of (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-Amino-2-oxoethyl)-2-(3-amino-3-oxopropyl)-11,20,29-tris(4-aminobutyl)-26-(3-guanidinopropyl)-17-isopropyl-5,14-dimethyl-23-(2-(methylthio)ethyl)-4,7,10,13,16,19,22,25,28,31-decaoxo-3,6,9,12,15,18,21,24,27,30-decaazatetratetracontan-1-oic acid Using HRMS and NMR". Environ. Sci. Technol., 2019, 1783, (2), 9691-9721.
  4. Mueller T, Schmidt R K. "Forced Degradation Studies to Evaluate (2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-(2-氨基-2-氧代乙基)-2-(3-氨基-3-氧代丙基)-11,20,29-四(4-氨基丁基)-26-(3-胍基丙基)-17-异丙基-5,14-二甲基-23-(2-(甲硫基)乙基)-4,7,10,13,16,19,22,25,28,31-十氧代-3,6,9,12,15,18,21,24,27,30-十氮杂tratetracontan-1-酸 Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2018, 1287, (11), 7913-7935.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...